Belite Bio (BLTE) Other financing activities (2023 - 2025)

Belite Bio's (BLTE) quarterly Other financing activities came in at $1.4 million in Q4 2025, down 96.24% year-on-year from $36.9 million in Q4 2024, and down 96.24% quarter-over-quarter from $36.9 million in Q4 2024.

Belite Bio (BLTE) Other financing activities (2023 - 2025) Analysis & Trends

Belite Bio's Other financing activities history runs 3 years deep, the most recent figure standing at $1.4 million for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.39 Mn
Dec 31, 2025 1.39 Mn
Dec 31, 2024 36.88 Mn
Dec 31, 2024 36.88 Mn
Dec 31, 2023 21.65 Mn
Dec 31, 2023 21.65 Mn